A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Abstract Text:

Takeshi Kato,Hideyuki Mishima,Masakazu Ikenaga,Kouhei Murata,Hideyuki Ishida,Mutsumi Fukunaga,Hirofumi Ota,Shusei Tominaga,Tadashi Ohnishi,Masahiro Amano,Kimimasa Ikeda,Masataka Ikeda,Mitsugu Sekimoto,Junichi Sakamoto,Morito Monden,Takeshi Kato,Hideyuki Mishima,Masakazu Ikenaga,Kouhei Murata,Hideyuki Ishida,Mutsumi Fukunaga,Hirofumi Ota,Shusei Tominaga,Tadashi Ohnishi,Masahiro Amano,Kimimasa Ikeda,Masataka Ikeda,Mitsugu Sekimoto,Junichi Sakamoto,Morito Monden,Takeshi Kato,Hideyuki Mishima,Masakazu Ikenaga,Kouhei Murata,Hideyuki Ishida,Mutsumi Fukunaga,Hirofumi Ota,Shusei Tominaga,Tadashi Ohnishi,Masahiro Amano,Kimimasa Ikeda,Masataka Ikeda,Mitsugu Sekimoto,Junichi Sakamoto,Morito Monden,

The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer. In all, 60 metastatic colorectal cancer patients with measurable disease were enrolled. The schedule of the treatment consisted of a 90 min intravenous (IV) infusion of irinotecan 150 mg/m(2) for on days 1 and 15, and 600-1,000 mg/body of oral doxifluridine on days 3-14 and 17-28. Cycles were repeated every 35 days. A median of three cycles of the combination therapy (range 1-14 cycles) was administered. A total of 57 patients (95%) completed at least two cycles of the therapy without any dose reductions. There was one complete response and 23 partial responses with an overall response rate of 40% [95% confidence interval (CI): 28-53%]. A total of 19 patients had stable disease, 43(72%) achieved disease control. The median time to progression was 5.9 months and the median overall survival was 20.5 months. Ten (17%) and 17 (28%) patients developed Grade 3-4 leukopenia and neutropenia, respectively. Grade 3-4 fatigue was observed in 7(12%) patients, nausea in five (8%), vomiting in four (7%), and diarrhea,in three (5%) patients. No treatment-related deaths were noted during the study. From these results, the combination of sequential irinotecan and doxifluridine is considered to be an effective, easy-to-administer regimen with acceptable tolerability.

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Publishing Authors By Initials

T Kato,H Mishima,M Ikenaga,K Murata,H Ishida,M Fukunaga,H Ota,S Tominaga,T Ohnishi,M Amano,K Ikeda,M Ikeda,M Sekimoto,J Sakamoto,M Monden,T Kato,H Mishima,M Ikenaga,K Murata,H Ishida,M Fukunaga,H Ota,S Tominaga,T Ohnishi,M Amano,K Ikeda,M Ikeda,M Sekimoto,J Sakamoto,M Monden,T Kato,H Mishima,M Ikenaga,K Murata,H Ishida,M Fukunaga,H Ota,S Tominaga,T Ohnishi,M Amano,K Ikeda,M Ikeda,M Sekimoto,J Sakamoto,M Monden,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer chemotherapy and pharmacology

VOLUME: 61

Page Numbers: 275-81

Journal Abbreviation: Cancer Chemother. Pharmacol.

ISSN: 0344-5704

DAY: 11

MONTH: 04

YEAR: 2007

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7806519

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.

AFFILIATION: Minoh City Hospital, 5-7-1 Kayano, Minoh City, Osaka, 562-8562, Japan.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer Related Publications

• A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
• Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization.
• CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells.
• Changes of proteasomes and cathepsins activities and their expression during differentiation of C2C12 myoblasts.
• Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
• Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma.
• Direct evidence of the production of IgA by tonsillar lymphocytes and the binding of IgA to the glomerular mesangium of IgA nephropathy patients.
• Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus.
• Gene expression of colorectal cancer: Preoperative genetic diagnosis using endoscopic biopsies.
• Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives.
• Hyperparathyroidism in a patient with Maffucci's syndrome: A case report.
• Impact of graft size on postoperative thrombocytopenia in living donor liver transplant.
• Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells.
• Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
• Involvement of interleukin-6 in activation of lysosomal cathepsin and atrophy of muscle fibers induced by intramuscular injection of turpentine oil in mice.
• Japanese guidelines for prevention of perioperative infections in urological field.
• Long-term and short-term evaluation of esophageal reconstruction using the colon or the jejunum in esophageal cancer patients after gastrectomy.
• Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells.
• Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
• Postoperative hyperbilirubinemia and graft outcome in living donor liver transplantation.
• Use of a metallic-wall stent in the magnet compression anastomosis technique for bile duct obstruction after liver transplantation.
• Vitamin K2 has growth inhibition effect against hepatocellular carcinoma cell lines but does not enhance anti-tumor effect of combination treatment of interferon-alpha and fluorouracil in vitro.
• [A case of hepatocellular carcinoma with right atrium tumor thrombus treated with combined doxorubicin and interferon-beta/intra-arterial injection chemotherapy and hepatectomy]
• [A case of intrathoracic multiple schwannoma and a review of the Japanese literature]
• [A case of pulmonary plasma cell granuloma in a child]
• [A case of successfully treated sigmoid colon cancer with multiple regional metastases by chemotherapy and radiation therapy]
• [A case treated with broncho-cutaneous stoma for postoperative bronchial stump fistula]
• [Analysis of the 25-patient who underwent a removal of W-spiral catheter after cessation of hepatic arterial infusion chemotherapy]
• [Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination]
• [Surgical treatment for peritoneal seeding and needle-tract implantation of hepatocellular carcinoma after ultrasound-guided percutaneous puncture]